Cell Culture Service, a supplier of custom cells and cell-based reagents, has been acquired by Evotec for $1.5 million upfront plus as much as $1.4 million in milestone fees. Evotec said the deal would improve its ability to offer integrated drug discovery and early development services for drugmakers. "CCS' experience and technologies for large-scale cell production are a perfect fit with Evotec's screening and in vitro pharmacology activities," Evotec COO Mario Polywka said.
Evotec buys custom cells and reagents supplier
SmartBrief Job Listings for Health Care
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan